Background The Norwegian Medicines Agency asked the Norwegian Knowledge Centre for the Health Services to review the documentation for antipsychotic drugs in order to evaluate differences in efficacy and safety between the various drugs used for schizophrenia in adults.
Methods We searched systematically for literature in the Cochrane Library, Medline, Embase and PsychInfo. We evaluated all identified reviews according to predefined inclusion criteria and appraised the methodological quality of the included systematic reviews.
Results We included six systematic reviews. We extracted and analyzed results on the efficacy or safety of first generation antipsychotics (typical antipsychotics) versus second generation antipsychotics (atypical antipsychotics) and among the various second generation antipsychotics. Of 99 possible comparisions, data were available on only 30. We found few differences in efficacy. However, haloperidole showed less efficacy than amisulpride and clozapine, and olanzapine led to greater improvement in functional capacity than quetiapine and ziprasidone. With respect to efficacy measured as symptom response among the second generation antipsychotics there were no differences. For adverse events, metabolic adverse events were most obvious for the second-generation antipsychotic drug olanzapine followed by clozapine and quetiapine, and extrapyramidal adverse events were most obvious for the first- generation antipsychotic drugs haloperidole and perfenazine. There were no differences in extrapyramidal symptoms among the second generation antipsychotics, except that quetiapin caused extrapyramidal symptoms in a greater proportion of patients than risperidon. There were no or few differences between the groups regarding cardiovascular, anticholinergic and hormonal adverse events as well as for discontinuation.
Conclusion We found few differences in efficacy between first- and second- generation antipsychotic drugs, and among the second generation antipsychotics. For adverse events there were reported differences for at least one type of adverse event for the majority of the comparisons.
Preliminary version: HTML in process
- NLM CatalogRelated NLM Catalog Entries
- Review An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.[Hum Psychopharmacol. 2011]Review An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.Krzystanek M, Krupka-Matuszczyk I. Hum Psychopharmacol. 2011 Jan; 26(1):81-5. Epub 2011 Feb 9.
- Review Off-Label Use of Atypical Antipsychotics: An Update[ 2011]Review Off-Label Use of Atypical Antipsychotics: An UpdateMaglione M, Maher AR, Hu J, Wang Z, Shanman R, Shekelle PG, Roth B, Hilton L, Suttorp MJ, Ewing BA, et al. 2011 Sep
- [Antipsychotic Treatment of the Adult Patient in the Acute Phase of Schizophrenia].[Rev Colomb Psiquiatr. 2014][Antipsychotic Treatment of the Adult Patient in the Acute Phase of Schizophrenia].Bohórquez Peñaranda A, Gómez Restrepo C, García Valencia J, Jaramillo González LE, de la Hoz AM, Arenas Á, Tamayo Martínez N. Rev Colomb Psiquiatr. 2014; 44 Suppl 1:13-28. Epub 2015 Jul 4.
- Review Selection of atypical antipsychotics for the management of schizophrenia.[Ann Pharmacother. 2004]Review Selection of atypical antipsychotics for the management of schizophrenia.Sprague DA, Loewen PS, Raymond CB. Ann Pharmacother. 2004 Feb; 38(2):313-9. Epub 2003 Dec 30.
- Review Atypical antipsychotics: mechanism of action.[Can J Psychiatry. 2002]Review Atypical antipsychotics: mechanism of action.Seeman P. Can J Psychiatry. 2002 Feb; 47(1):27-38.
- Efficacy and Safety of First-Generation and Second-Generation Anti-Psychotic Dru...Efficacy and Safety of First-Generation and Second-Generation Anti-Psychotic Drugs for Schizophrenia in Adults: An Overview of Systematic Reviews
- The Use of Naltrexone in Low Doses Beyond the Approved IndicationThe Use of Naltrexone in Low Doses Beyond the Approved Indication
Your browsing activity is empty.
Activity recording is turned off.
See more...